Lappoxo

Omeprazole, the active ingredient in Lappoxo, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease and erosive esophagitis.

GNH USA supplies Lappoxo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that addresses conditions caused by excess gastric acid.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and acid regurgitation. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence. - Erosive esophagitis: heals inflamed esophageal tissue and reduces further damage. - Helicobacter pylori eradication (in combination therapy): enhances bacterial clearance when used with antibiotics.

Adverse reactions may occur with omeprazole use.

Common Side Effects: - Headache: mild to moderate intensity. - Abdominal pain: discomfort in the upper abdomen. - Diarrhoea: loose stools occurring intermittently. - Nausea: feeling of queasiness.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of swelling, rash, and breathing difficulty. - Clostridioides difficile infection: severe diarrhoea with abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle weakness, tremors, or cardiac arrhythmia.

Before initiating therapy, consider the following precautions.

- Assess renal function: adjust use in patients with severe impairment. - Review concomitant medications: avoid drugs that may interact adversely. - Monitor magnesium status: consider supplementation during long‑term therapy. - Use with caution in the elderly: increased risk of fractures and falls. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Omeprazole can affect the pharmacokinetics of several medicines.

Major Interactions (Avoid): - Ketoconazole: reduced absorption and efficacy. - Atazanavir: decreased antiviral activity. - Clopidogrel: diminished antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Digoxin: potential rise in serum levels, watch for toxicity.